Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04252287 · ClinicalTrials.gov registry record · Phase 3
A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure
A Phase 3 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 3
- Development phase
- 476
- Enrollment target
NCT04252287 is a Phase 3 study that has completed, run by Janssen Research & Development. The registered enrollment target is 476 participants.
The verdict
NCT04252287, a Phase 3 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 476 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the superiority of the effectiveness of canagliflozin 100 milligram (mg) daily versus placebo in participants with symptomatic heart failure (HF) in improving the overall Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score (TSS).
Interventions
- DRUG Placebo
- DRUG Canagliflozin 100 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 476 participants |
| Start Date | 2020-03-10 |
| Est. Completion | 2021-11-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04252287
The ClinicalTrials.gov registry entry for NCT04252287 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 476 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Janssen Research & Development, which has 593 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04252287 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04252287 about?
NCT04252287 is a clinical study titled "A Study on Impact of Canagliflozin on Health Status, Quality of Life, and Functional Status in Heart Failure". The purpose of this study is to determine the superiority of the effectiveness of canagliflozin 100 milligram (mg) daily versus placebo in participants with symptomatic heart failure (HF) in improving the overall Kansas City Cardiomyopathy Questionnaire (KCCQ) Total Symptom Score (TSS).
What is the current status of trial NCT04252287?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 476 participants. The study started on 2020-03-10. Estimated completion is 2021-11-09.
What interventions are being tested in trial NCT04252287?
The interventions under investigation include: Placebo (DRUG), Canagliflozin 100 mg (DRUG).
Who is sponsoring clinical trial NCT04252287?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.